Two PD-1 blocking agents have received tissue-agnostic approval based on DNA repair status or mutational burden since 2017 13, yet their performance in PCa is at best questionable, and attempts at targeting other checkpoint molecules have similarly failed in performing under recent data from clinical trials despite showing promise in early stages. This evidence concerns the gene PDCD1 and posterior cortical atrophy.